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Abstract
We previously reported that cooperative RAS-MET signaling drives disease progression in NF1-related MPNSTs, and that MET inhibition results in downstream inhibition of RAS/MAPK in the context of MET amplification. This study revealed that response to MET inhibition appeared to be modulated by P53 gene status. It is currently unclear how P53 function affects kinome signaling and response to kinase inhibition. Here we utilized genetically engineered mouse models with variable levels of Met and Hgf amplification and differential p53 status (NF1 
Introduction
Cooperative RAS/ERK and HGF/MET signaling promotes cancer progression and therapy resistance, yet the mechanisms that mediate these complex signaling interactions are not well understood. Recent studies support the concept that cooperative RAS-MET signaling is influenced by genomic alterations and feedback within the MET and RAS signaling pathways.
Neurofibromatosis type 1 (NF1) is a tumor predisposition syndrome caused by germline mutations in the NF1 gene which encodes neurofibromin, a GTPase-activating protein that regulates RAS signaling (1, 2) . Approximately 8-13% of individuals with NF1 will develop malignant tumors, most commonly Malignant Peripheral Nerve Sheath Tumors (MPNSTs) (3).
NF1-related MPNSTs are chemorefractory sarcomas that frequently metastasize and have fiveyear survival rates ranging from 20-50% (4-8). MET-RAS signaling is implicated in NF1-related
MPNSTs. MPNSTs often develop from MET-overexpressing plexiform neurofibromas and commonly exhibit MET and HGF gene amplifications (9, 10) . These genomic alterations occur in the backdrop of putative RAS deregulation from germline loss of NF1-mediated tumor suppression, and NF1 loss-of-heterozygosity events in the MPNST cell of origin. Moreover, MET phosphorylation is observed in at least half of MPNSTs and combined inhibition of MET/VEGFR (cabozantinib) mitigated tumor growth in a preclinical MPNST model (11) .
Aberrant MET signaling is known to drive malignant progression in a variety of RAS deregulated tumors in humans, as well as therapy resistance (12) . MET has also been found to drive resistance to RAS pathway inhibition in several cancers, including melanoma and colorectal cancer (13, 14) We recently showed that MET overexpression, as a result of MET amplification in NF1-null Schwann cells, is sufficient for malignant transformation and that MET amplified MPNSTs respond exquisitely to targeted MET inhibition (15) . We also conducted a longitudinal genomic analysis to identify key genetic events underlying transformation of a human plexiform neurofibroma to MPNST (15) . Our results revealed that there is early positive selection for MET and HGF copy number gain during human MPNST progression that precedes both the accumulation of other oncogene amplifications and additional losses of tumor suppressor genes. In order to validate these findings, we designed a unique mouse model of MET amplification in p53 wild type, NF1-null myelinating cells (NF1 In addition to MET and HGF copy number variations, NF1-related MPNSTs also exhibit highly complex genomic structural variations leading to additional genomic gains and losses that appear to be non-random and adaptive for MPNST progression (15) (16) (17) . Consistent genomic alterations have been identified in MPNSTs, most notably mutations in the CDKN2A and TP53
tumor suppressors (18) (19) (20) . Recent work confirms that clonal heterogeneity is attributable to NF1/P53 and NF1/CDKN2A deficiency due to the formation of tumorigenic stem cells (21) .
While it is unclear whether P53 and CDKN2A mutations affect kinase signaling, MET activation has been proposed as a stem cell marker in P53-deficient breast cancer lines. A recent study showed that Met amplifications promote a stem cell phenotype in the context of P53-deficiency suggesting that the pleiotropic effects of MET activation support the stem cell niche (22, 23) .
Other studies present evidence that HGF/MET activation is directly regulated through P53 (24, 25 (32) . In this study, we used the MEK inhibitor trametinib (Mekinist) which is a reversible, highly selective, allosteric inhibitor of MEK1 and MEK2, and is FDA approved for metastatic melanoma. One of the challenges of targeting the MEK/ERK pathway is achieving high level MEK inhibition without systemic toxicity. Trametinib has a strong pharmacokinetic profile with exceptional potency and specificity, oral bioavailability, and long half-life with a shallow C max (peak concentration) to C trough (trough concentration) profile (33) . To compare the effects of MET and MEK inhibition in MPNSTs, we performed in vivo and in vitro preclinical studies with single agent capmatinib or trametinib. We also included the standard chemotherapy agent doxorubicin which is commonly used to treat MPNST patients yet achieves minimal response. Tumorgrafts were established in immunocompromised mice from primary MPNSTs in the NF1-MET, NF1-P53, and NF1 models as previously described (15) .
Transplanted tumors were allowed to grow until tumor volume was approximately 150mm 3 
Differential response to MEK and MET inhibitors is associated with P53 status
We hypothesized that our MPNST models would demonstrate distinct growth patterns and kinome adaptation to MET and MEK inhibition. In NF1-MET (p53 wild type) MPNSTs we observed exquisite sensitivity to single agent capmatinib as well as significant tumor growth inhibition with trametinib (p < 1.0e -16 ; both capmatinib and trametinib treatments); however, pairwise comparison revealed that capmatinib was significantly more effective than trametinib in the NF1-MET tumors (p < 0.0004; Figure 1A We also evaluated the efficacy of MET and MEK inhibition in P53 wild type, NF1 tumors which had a significantly slower growth rate compared to NF1-MET and NF1-P53 tumors ( Figure 3A ).
NF1 tumor growth was suppressed with capmatinib (p < 0.0009) and trametinib (p < 1.0e -16 ), but
was not significantly inhibited with doxorubicin (p < 0.07) ( Figure 3A) . Figure 1C) . These results indicate that NF1-related MPNSTs without Met amplification or p53 loss may also be responsive to combination MET and MEK inhibition.
Combination MET and MEK inhibition prevents adaptive ERK and AKT response
Differential patterns of ERK inactivation and activation were observed in response to monotherapy vs. combination kinase inhibition in the NF1 models. Overall, combined MET and MEK inhibition resulted in a greater than 90% reduction in MET and ERK activation in all of the MPNST models ( Figure 4A and Figure 5A , right panels). In NF1-MET cells, ERK activation was significantly inhibited by 5 nM capmatinib, whereas NF1 and especially NF1-P53 cells showed a marginal decrease in pERK in response to capmatinib ( Figure 5B ). Trametinib was much more effective at inhibiting ERK activation and demonstrated reduction of pERK at 10nM in NF1-P53
and NF1-MET cells and at 5nM in NF1 cells ( Figure 5C ). Combined capmatinib and trametinib treatment mirrored the tumorgraft results ( Figure 5A ) and was the most effective treatment in decreasing pERK ( Figure 5D ). These findings validate the expected inhibition of RAS/ERK signaling with MEK TKIs. Moreover, these results emphasize the importance of combined kinase inhibition to eradicate RAS signaling (Figures 1-3 ).
Another major signaling pathway that is activated by MET and known to interact with RAF is the PI3K/AKT pathway. We observed high pAKT at the invasive edges of the NF1-P53 tumors, yet minimal pAKT was present in NF1-MET or NF1 tumors ( Figure 6A ). Interestingly, increased pAKT was observed in NF1-P53 tumors after capmatinib or trametinib treatment and persisted at the tumor periphery even with combined capmatinib and trametinib treatment ( Figure 6A ).
Analysis of AKT activity in the MPNST lines verified our in vivo observations. Even though AKT expression is comparable across the MPNST lines, pAKT is significantly higher in the NF1-P53 Figure 4D ) and resulted in a significant reduction in tumor growth compared to single agent alone (Figures 1-3) . As mentioned earlier, trametinib treatment resulted in increased pAKT in all three of the MPNST cells. Although combined MET and MEK inhibition suppressed AKT activation to its non-stimulated state, pAKT was not completely inhibited in the NF1-P53 and NF1 lines ( Figure 6D ). These observations strongly point to a robust compensation mechanism that allows for sustained AKT signaling despite abrogation of MET and MEK signaling. These results also confirm that MEK inhibition promotes MET activation, particularly when genomic HGF or MET alterations are present.
RAF reinforces RAS-AKT crosstalk in MPNSTs
An alternative explanation for trametinib-based activation of MET or sustained AKT activation with combination MET-MEK inhibition is that the drugs themselves modulate RAS-MET signaling independent of HGF. In order to address this question, and to assess the impact of capmatinib and trametinib therapy on the broader kinome, we performed experiments where we varied single agent and combination therapy concentrations, with and without HGF stimulation.
We One of the targetable mediators between the RAS and PI3K/AKT pathways is RAF (35, 36) .
Low BRAF expression was observed in NF1-MET cells compared to NF1-P53 cells and BRAF activation was not affected by MET or MEK inhibition ( Figure 7A-B) . Capmatinib was associated with mild activation of bRAF above basal state in the NF1-MET lines; however no change was noted in the NF1-P53 lines possibly due to saturation from overexpression.
Increase in pCRAF was observed with HGF treatment in both the NF1-MET and NF1-P53 cells.
Interestingly, capmatinib inhibited the effects of HGF stimulation on cRAF phosphorylation, but trametinib increased p-CRAF (in the presence of HGF), an effect that was mitigated by combined MET and MEK inhibition ( Figure 7A-B) . We observed a correlative pattern of total CRAF expression and activation similar to the relationship that is observed with RTK activation and receptor turnover. We also evaluated STAT signaling and observed a decrease in STAT3 activation in the presence of HGF in NF1-P53 cells but no change in NF1-MET cells ( Figure   7C-D) . However, in NF1-P53 cells, pSTAT3 increased in response to monotherapy of both capmatinib and trametinib and also combined capmatinib+trametinib treatment ( Figure 7D ). This was also observed to a weaker extent in NF1-MET cells ( Figure 7C ). Overall, this analysis of the RAS-AKT kinome reveals that P53 deficiency is associated with a high degree of baseline AKT activation that serves as a compensation point to promote survival in response to combined MET and MEK inhibition. Moreover, the data also supports the concept that 1) AKT activation is regulated through RAF and 2) AKT is activated by MEK inhibition but not MET inhibition. These findings identify key nodes that drive kinome robustness in the context of MET-addiction and P53 deficiency and reveal the inherent signaling feedback mechanisms that promote drug resistance in MPNSTs. Combination therapies, therefore, are better suited to target the diversity of kinase signaling pathways that drive disease progression. In order to address this concept in MPNSTs, we 1) determined the efficacy and kinome response to MET and/or MEK inhibition, 2) evaluated how P53 modulates kinome signaling, and 3) examined targetable points of signaling convergence between the RAS and MET pathways. Taken together, our data supports the concept that RAS-MET signal interactions are both essential to disease progression and targetable.
We tested the efficacy of single agent and combined inhibition of MET and MEK in MPNST models with variable levels of MET amplification and P53 deficiency. We discovered that NF1- By evaluating the MET and RAS signaling response to MET and/or MEK inhibition in our MPNST models, we were able to identify distinct kinome responses to MET or MEK inhibition.
We observed a differential pattern of kinase signaling between the P53-intact and P53-deficient models, and in response to MET and MEK inhibition. We also observed consistent patterns of kinome adaptation to single agent MET or MEK inhibition that could be applicable to other disease contexts as they occurred agnostic to P53 status, and ultimately led to therapy resistance in our models. In all of the MPNST models, combined MET and MEK inhibition was the most effective treatment for decreasing ERK activity. The fact that NF1-P53 tumors have a lower basal ERK activity and a variable response to MEK inhibition suggests that P53-deficient tumors may not be exclusively dependent on RAS-ERK signaling. This idea is supported by high basal AKT activity in NF1-P53 tumors that was rapidly increased upon MET or MEK inhibition. Given that we observed increase AKT activation in response to trametinib in all of our MPNST tumor models, PI3K/AKT pathway may be a robust compensation mechanism in RAS-deregulated MPNSTs. As with ERK, combined MET and MEK inhibition was the most effective treatment for decreasing activation of AKT. We did not evaluate all of the cross-talk candidates that could potentially activate AKT in the setting of RAS-MET inhibition, but our data suggest that both the BRAF and CRAF may play a role in activating AKT in response to MET or MEK inhibition.
Unexpectedly, we observed that trametinib treatment resulted in MET activation in all of the NF1 MPNST models. Trametinib-mediated MET activation was dependent on HGF and could be abrogated with the addition of capmatinib. Taken together, these data confirm that distinct compensation mechanisms drive resistance to capmatinib and trametinib therapy, and broadly implicate HGF/MET signal activation in resistance to MEK inhibition. Even though RAS signaling is not exclusively activated by MET, MET expression is significantly upregulated in RAS-transformed cells and is required for RAS-mediated tumorigenesis and metastasis (38, 39) . Observed resistance to mTOR inhibitors in breast, lung, and renal cell cancer is attributable to MET activation (40) , an effect that can be overcome through addition of a MET inhibitor (41) .
These data strongly point towards signaling convergence between the RAS and MET pathways in cancer and highlight a potential bi-directional mechanism of RAS-MET activation in the setting of tyrosine kinase inhibition and ligand-dependent activation of RAS.
There is an evolving conceptual framework that implicates P53 as a key regulatory protein for kinase signaling, either as an indirect driver of adaptive genomic alterations such as RTK amplifications, or through transcriptional regulation of oncogenic proteins such as VEGFR or heat-shock factor 1 (HSF1) leading to EGFR and ErbB2 signal activation (42, 43) . P53
haploinsufficiency was recently shown to cooperate with EGFR amplification to increase tumor grade in murine MPNSTs (44) . Another example of the connection between P53 and kinase signaling is the recent observation that mammary stem cell expansion in triple-negative breast cancer was shown to be dependent on P53 deficiency (23) . In this same study, MET activation was a direct consequence of P53 deficiency and promoted robust maintenance of the stem cell phenotype. Our data supports the integral role that P53 status in manipulating the kinome in cancer progression and therapeutic resistance.
In conclusion, this work extends our initial findings that MET is sufficient for malignant transformation of NF1-deficient peripheral nerve cells into MPNSTs and can be successfully targeted with a highly specific MET inhibitor (15) . Our demonstration of continued MET dependency following transformation and in the setting of MEK inhibition demonstrates the kinome adaptations that may exist in human MPNSTs. Our work verifies the significant role that MET signaling plays in reinforcing states of RAS activation and the ability of the RAS/ERK pathway to reinforce MET signaling. Based on the data presented, it is possible that MEK targeted therapy strategies can inadvertently activate MET resulting in broader TKI resistance.
MET compensation should be assessed when analyzing the therapeutic response to TKI's in RAS-addicted tumors.
Methods:
Histopathology Mouse tissues were fixed in 10% neutral buffered formalin for 72 hours (Thermo) prior to paraffin embedding and sectioning for histology and immunohistochemistry.
Immunohistochemistry was performed on formalin-fixed paraffin embedded samples using a citrate-based antigen retrieval system (Vector Labs). Samples were stained for phosphorylated MET (Cell Signaling D26 #3077), phosphorylated MAPK (Cell Signaling #9101), phosphorylated AKT (Cell signaling D9E #4060), and phosphorylated MEK (Cell Signaling 166F8 #2338) were performed using a Ventana autostainer. Images were obtained with an Aperio Digital Imaging system (Leica).
Western Blotting
Mouse derived cell lines NF1-p53, NF1-MET, and NF1 were grown to 90% confluency overnight by seeding plates with 500,000 -750,000 cells. Cells were then serum starved overnight and then treated with indicated inhibitors (capmatinib, trametinib, or combination) for 2 hours followed by 100ng/mL of HGF for 15 minutes. Cells were then washed with PBS and harvested in RIPA buffer plus protease inhibitor cocktail (Roche). Lysates (16-20 μg) were resolved on a 4%-20% TGX SDS-PAGE gel (Bio-Rad) and transferred to a PVDF membrane (Invitrogen).
After blocking for 1 hour with 5% dry milk in TBST buffer ( 
